| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
James LeBar last filed a Form 4 in March 2020, as Director at ZOMDF. James LeBar's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 20,000 shares of ZOMDF. The ZOMDF filings lean toward selling, a net 200,000 shares.
James LeBar has 4 Form 4 filings on record from January 2018 to March 2020, all as Director at Zomedica (ZOMDF), 2018–2020.
The 4 reported transactions were 2 option or other derivative awards, 1 open-market sale and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $430K.
The only open-market sale was 200,000 shares of ZOMDF at an average $2.15 on August 28, 2018, about $430K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2018 | ZOMDF Zomedica Corp. | Director | Sell | 200,000 | $2.15 | $430,000.00 | -90.9% |